Engineered T cell therapies, including CAR-T cells, have shown tremendous promise as cancer treatments. However, they have so far shown efficacy for only some types of cancer. We design and use high throughput screening approaches to understand the signaling pathways and cell phenotypes that make T cell therapies effective. We use this information to aid in our design of more persistent, effective CAR T cells.
Selected publications:
Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Gordon, K. S., Kyung, T., Perez, C. R., Holec, P. V., Ramos, A., Zhang, A. Q., Agarwal, Y., Liu, Y., Koch, C. E., Starchenko, A., Joughin, B. A., Lauffenburger, D. A., Irvine, D. J., Hemann, M. T., & Birnbaum, M. E. Nature Biomedical Engineering, 6(7), 855–866 (2022). https://doi.org/10.1038/s41551-022-00896-0
Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence. Perez, C. R., Garmilla, A., Nilsson, A., Baghdassarian, H. M., Gordon, K. S., Lima, L. G., Smith, B. E., Maus, M. V., Lauffenburger, D. A., & Birnbaum, M. E. bioRxiv, (2024). https://doi.org/10.1101/2024.04.29.591541
Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma. Gordon, K. S., Perez, C. R., Garmilla, A., Lam, M. S. Y., Aw, J. J., Datta, A., Lauffenburger, D. A., Pavesi, A., & Birnbaum, M. E. bioRxiv, (2024). https://doi.org/10.1101/2024.04.04.586240